157 related articles for article (PubMed ID: 11831112)
21. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
[TBL] [Abstract][Full Text] [Related]
22. Thiazolidinediones -- some recent developments.
Stumvoll M
Expert Opin Investig Drugs; 2003 Jul; 12(7):1179-87. PubMed ID: 12831352
[TBL] [Abstract][Full Text] [Related]
23. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
24. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
25. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.
Guo L; Tabrizchi R
Pharmacol Ther; 2006 Jul; 111(1):145-73. PubMed ID: 16305809
[TBL] [Abstract][Full Text] [Related]
27. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
28. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
29. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
Rieusset J; Touri F; Michalik L; Escher P; Desvergne B; Niesor E; Wahli W
Mol Endocrinol; 2002 Nov; 16(11):2628-44. PubMed ID: 12403851
[TBL] [Abstract][Full Text] [Related]
30. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Sugiyama Y; Murase K; Ikeda H
Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
[TBL] [Abstract][Full Text] [Related]
32. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Gurnell M; Savage DB; Chatterjee VK; O'Rahilly S
J Clin Endocrinol Metab; 2003 Jun; 88(6):2412-21. PubMed ID: 12788836
[TBL] [Abstract][Full Text] [Related]
33. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
Ahsan W
Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
[TBL] [Abstract][Full Text] [Related]
34. Regulation of energy metabolism by long-chain fatty acids.
Nakamura MT; Yudell BE; Loor JJ
Prog Lipid Res; 2014 Jan; 53():124-44. PubMed ID: 24362249
[TBL] [Abstract][Full Text] [Related]
35. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Berger J; Bailey P; Biswas C; Cullinan CA; Doebber TW; Hayes NS; Saperstein R; Smith RG; Leibowitz MD
Endocrinology; 1996 Oct; 137(10):4189-95. PubMed ID: 8828476
[TBL] [Abstract][Full Text] [Related]
36. [Significance of PPAR gamma (peroxisome proliferator-activated receptor gamma) in atherosclerosis].
Itoh H; Nakao K
Nihon Rinsho; 2001 Feb; 59 Suppl 2():602-16. PubMed ID: 11351658
[No Abstract] [Full Text] [Related]
37. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
38. [PPARgamma and insulin resistance].
Girard J
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S19-22. PubMed ID: 12037503
[TBL] [Abstract][Full Text] [Related]
39. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
40. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Sugiyama Y; Taketomi S; Shimura Y; Ikeda H; Fujita T
Arzneimittelforschung; 1990 Mar; 40(3):263-7. PubMed ID: 2189419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
